Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Billionaire Ken Fisher’s Top 5 Dividend Stock Picks

In this article, we will take a look at Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. For deeper discussion and analysis, read Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. 

Ken Fisher of Fisher Asset Management

5. UnitedHealth Group Incorporated (NYSE:UNH)

Fisher Asset Management’s Stake Value: $1,417,269,746

On June 4, Morgan Stanley raised the firm’s price recommendation on UnitedHealth Group Incorporated (NYSE:UNH) to $453 from $395.  It reiterated an Overweight rating on the shares. Analyst Erin Wright noted that managed care stocks have been “grinding higher” as signs of softer utilization trends have started to emerge. The analyst also pointed to the potential impact of artificial intelligence across the managed care industry, saying AI could benefit both revenue growth and cost management. As those efficiencies scale, Morgan Stanley believes they could generate roughly 45% average EPS upside across the sector.

On June 8, Mizuho raised its price goal on UnitedHealth to $460 from $440. It maintained an Outperform rating on the stock. The firm said it believes the managed care sector is moving into a “more stable and predictable” policy environment. According to the analyst, the size and frequency of policy-related surprises are likely to ease from the elevated levels seen over the past three years. That shift could allow investors to focus more on company fundamentals, pricing recovery, and the sector’s underlying earnings potential. Mizuho also increased price targets across the managed care sector to reflect what it sees as a more stable regulatory and legislative backdrop.

UnitedHealth Group Incorporated (NYSE:UNH) is a healthcare and well-being company. Its operations are organized across four segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. The UnitedHealthcare business includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, and UnitedHealthcare Community & State.

4. Johnson Controls International plc (NYSE:JCI)

Fisher Asset Management’s Stake Value: $2,295,097,372

On June 3, Wolfe Research raised its price recommendation on Johnson Controls International plc (NYSE:JCI) to $171 from $165. It reiterated an Outperform rating on the stock. The firm came away encouraged after Johnson Controls’ investor event, which highlighted the changes taking place across the company. According to the analyst, the presentation provided a clearer view of management’s ongoing initiatives and “showed us that the lean transformation is real.” The update suggested that efforts to streamline operations and improve execution are moving beyond the planning stage and beginning to show tangible progress.

On June 2, UBS also became more bullish on the company, raising its price target to $180 from $170. It kept a Buy rating on the shares. In a research note, the analyst said Johnson Controls’ operational turnaround is producing promising early signs. While the transformation is still underway, UBS believes the initial results support management’s strategy and point to improving performance.

Johnson Controls International plc (NYSE:JCI) is a global technology company that focuses on energy efficiency, decarbonization, thermal management, and mission-critical performance. The company helps customers use energy more efficiently, reduce carbon emissions, and maintain reliable operations in industries where precision and resilience are increasingly important.

3. Merck & Co., Inc. (NYSE:MRK)

Fisher Asset Management’s Stake Value: $3,180,020,742

Reuters reported on June 1 that Merck & Co., Inc. (NYSE:MRK) is holding discussions with global health authorities about making its COVID-19 antiviral pill, molnupiravir, available as a treatment option for Ebola. The move came amid a growing outbreak in the Democratic Republic of Congo, according to a senior company executive. The outbreak has affected an estimated 1,100 people. It has also led to 42 deaths. It involves the Bundibugyo strain of the Ebola virus, a rare variant for which no approved vaccines or treatments currently exist.

Molnupiravir was developed by the New Jersey-based pharmaceutical company in partnership with Ridgeback Biotherapeutics and is marketed under the brand name Lagevrio. The drug received emergency authorization from the Food and Drug Administration during the COVID-19 pandemic for the treatment of mild-to-moderate COVID-19 in adults considered at high risk of developing severe illness.

While molnupiravir is not approved for the treatment of Ebola, animal studies have demonstrated some effectiveness against the virus. The drug could potentially help prevent Ebola infections among individuals at elevated risk of exposure. Its use is not recommended during pregnancy.

Merck also manufactures Ervebo, an Ebola vaccine approved for protection against the more common Zaire Ebola virus. Barr said the technology behind Ervebo could prove useful in the development of a new vaccine targeting the Bundibugyo strain.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that provides prescription medicines, including biologic therapies and vaccines, as well as animal health products.

2. Costco Wholesale Corporation (NASDAQ:COST)

Fisher Asset Management’s Stake Value: $3,208,361,404

On June 3, Costco Wholesale Corporation (NASDAQ:COST) reported net sales of $24.01 billion for May. It represents a 14.5% increase from the same month last year. The retailer also continued to post solid growth on a year-to-date basis. Net sales for the first 39 weeks of the fiscal year totaled $221.19 billion, up 10% from $201.02 billion in the comparable period a year earlier.

Comparable sales for the four weeks ended May 31, 2026, increased 12.5%, the company said. The US remained Costco’s strongest market, with comparable sales rising 13.7%. Canada recorded a 9.2% increase, while other international markets posted growth of 9.7%.

Online demand also stayed strong. E-commerce comparable sales jumped 21.1% during the month. When adjusted for changes in gasoline prices and foreign exchange rates, comparable sales increased 8%. On the same basis, comparable sales rose 8.7% in the U.S. and 5.3% in Canada.

Costco Wholesale Corporation (NASDAQ:COST) operates a network of membership warehouses and e-commerce sites, offering both nationally branded and private-label products across a wide range of merchandise categories.

1. Broadcom Inc. (NASDAQ:AVGO)

Fisher Asset Management’s Stake Value: $4,547,124,089

On June 4, DA Davidson raised its price recommendation on Broadcom Inc. (NASDAQ:AVGO) to $400 from $375. It reiterated a Neutral rating on the stock. The firm noted that Broadcom shares declined despite the company delivering a modest Q1 revenue beat of 0.5% compared to consensus estimates and issuing a constructive Q3 outlook. According to the analyst, the guidance fell short of the market’s elevated expectations. During the earnings call, Broadcom also provided updates on several strategic initiatives. DA Davidson said these developments indicate that supply and demand remain out of balance, with demand for computing power continuing to increase.

A day later, on June 5, Erste Group upgraded Broadcom to Buy from Hold. The analyst told investors that Broadcom is growing at a much faster pace than its industry peers and expects the stock to maintain its upward momentum, supported by the company’s stronger-than-average growth prospects.

Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies semiconductor products, enterprise software, and security solutions. The company operates through two business segments: semiconductor solutions and infrastructure software.

While we acknowledge the potential of AVGO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVGO and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Oversold Dividend Growth Stocks to Buy and 10 No-Brainer Dividend Stocks to Buy

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.